Peptides / Weight and metabolic

Synthetic analog · 44 amino acids · 4,858 Da

Lixisenatide

ApprovedNot banned in sport

Lixisenatide (Adlyxin) is a GLP-1 receptor agonist approved in the US for type 2 diabetes, while its single-drug EU form was withdrawn for commercial reasons. Studies in people tested it mostly on blood sugar, weight and kidney function, and tracked stomach side effects. PepBank shows 652 results on lixisenatide from 96 studies in people, and 116 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Adlyxin, Lyxumia

First 40 of 44 amino acids0 changed amino acids

Evidence level: Large trials in people652 of 768 results come from studies in people, including randomized trials.

Results in people

652

85% of 768 results

Results in animals

11% of 768 results

Results in lab cells

4% of 768 results

From computer models

0% of 768 results

Overview

Lixisenatide at a glance

What it is	Synthetic analog, 44 amino acids
Approval	Approved in the US (Adlyxin, 2016)
In sport	Not listed as banned by WADA
Studies	116 studies with results. 115 of them gave lixisenatide, with 768 results. 652 in people84 in animals32 in lab cells
Best study in people	Randomized controlled trial with 6,068 people (2015)
Clinical trials	67 registered: 5 active or planned, 27 with posted results
Community use	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

The science

What is lixisenatide?

Lixisenatide is a 44-residue peptide agonist of the GLP-1 receptor.

Amino acids in one chain

The history of lixisenatide

2008June
A registered trial of lixisenatide started (NCT00712673).
2010
The oldest paper on lixisenatide in PepBank is from 2010.
2016July
FDA approved Adlyxin for adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Lixisenatide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 44 amino acidsFrom the first amino acid to the last

H1G−EGT5FTS−DL10S+KQM−E15−E−EAV+R20LFI−EW25L+KNGG30PSSGA35PPS+K+K40+K+K+K+K

Darker means more water-repelling+ and − show charge in the body

Structure

Lixisenatide is a synthetic analog of 44 amino acids, with no ring, no changed amino acids.

Formula

C₂₁₅H₃₄₇N₆₁O₆₅S

Molecular weight

4,858 g/mol

CAS number

320367-13-3

Target

Glucagon-like peptide 1 receptor (gene GLP1R): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 90472060, ChEMBL CHEMBL2108336, UNII 74O62BB01U, DrugBank DB09265

Full sequence, SMILES and InChIKey

InChIKey
XVVOERDUTLJJHN-IAEQDCLQSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N

See charge, composition and 3D structure on the Scientific page

The evidence

What lixisenatide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people652 of 768 results come from studies in people, including randomized trials.

Blood sugar

353 results · 345 in people · 7 animal · 1 lab

In adults with diabetes on metformin, lixisenatide met the trial's noninferiority criterion despite a numerically smaller HbA1c reduction than exenatide. Diabetes care, 2013

Top results

In adults with diabetes on metformin, lixisenatide met the trial's noninferiority criterion despite a numerically smaller HbA1c reduction than exenatide. (Diabetes care, 2013)
In type 1 diabetes, lixisenatide reduced glucagon exposure after a mixed meal compared with placebo. (Endocrinology, diabetes & metabolism, 2020)
In Japanese patients with type 2 diabetes, adding lixisenatide to glargine reduced HbA1c more than glargine. (Diabetes, obesity & metabolism, 2020)

Weight and appetite

43 results · 42 in people · 1 animal

In patients with diabetes on basal insulin, lixisenatide reduced body weight more than placebo. Diabetes, obesity & metabolism, 2018

Top results

In patients with diabetes on basal insulin, lixisenatide reduced body weight more than placebo. (Diabetes, obesity & metabolism, 2018)
In healthy participants after lixisenatide, energy intake was not linked to total stomach content. (Nutrients, 2020)
In healthy participants, lixisenatide reduced meal energy intake compared with placebo. (Nutrients, 2020)

Kidneys and bladder

26 results · 25 in people · 1 animal

In patients with diabetes, lixisenatide did not affect kidney filtration after a meal compared with insulin glulisine. Diabetes, obesity & metabolism, 2017

Top results

In patients with diabetes, lixisenatide did not affect kidney filtration after a meal compared with insulin glulisine. (Diabetes, obesity & metabolism, 2017)
In people with diabetes and kidney disease in a lixisenatide trial, Klotho levels did not change significantly. (Diabetes, obesity & metabolism, 2026)
In patients with diabetes, lixisenatide increased absolute and fractional sodium, chloride, and potassium excretion after breakfast versus insulin glulisine. (American journal of physiology. Renal physiology, 2019)

Stomach and gut

23 results · 23 in people

Lixisenatide slowed gastric emptying versus placebo in healthy participants. Diabetes, obesity & metabolism, 2019

Top results

Lixisenatide slowed gastric emptying versus placebo in healthy participants. (Diabetes, obesity & metabolism, 2019)
In adults with diabetes, reflux episodes were numerically fewer with lixisenatide than liraglutide, without a significant difference. (Diabetes care, 2020)
In healthy participants, lixisenatide slowed stomach emptying compared with placebo. (Nutrients, 2020)

Heart and blood vessels

43 results · 17 in people · 20 animal · 6 lab

After breakfast, upper blood pressure tended to be higher with lixisenatide than with insulin glulisine. Hypertension, 2018

Top results

After breakfast, upper blood pressure tended to be higher with lixisenatide than with insulin glulisine. (Hypertension, 2018)
Lixisenatide did not change fasting circulation measurements compared with insulin glulisine in patients with type 2 diabetes. (Hypertension, 2018)
In people with diabetes and kidney disease, lixisenatide did not significantly change aortic stiffness compared with placebo. (Diabetes, obesity & metabolism, 2026)

Cholesterol and blood fats

9 results · 9 in people

Lixisenatide reduced CM-TAG pool size versus placebo in obese men with diabetes. The Journal of clinical endocrinology and metabolism, 2019

Top results

Lixisenatide reduced CM-TAG pool size versus placebo in obese men with diabetes. (The Journal of clinical endocrinology and metabolism, 2019)
In patients with diabetes, triglycerides increased less with iGlarLixi than insulin glargine at week 30. (Diabetes, obesity & metabolism, 2019)
Lixisenatide did not reduce VLDL-TAG pool size versus placebo in obese men with diabetes. (The Journal of clinical endocrinology and metabolism, 2019)

Lixisenatide has 428 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 116 lixisenatide studies by area Open the Scientific page

Key lixisenatide studies

Studies in people come first, then studies in animals and in the lab.

People
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer et al. 2015 · The New England journal of medicine · 6,068 people · cited by 1,765
8 results
People
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Rosenstock et al. 2013 · Diabetes care · 634 people · cited by 200
10 results
People
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial
Terauchi et al. 2020 · Diabetes, obesity & metabolism · 521 people · cited by 36
6 results
People
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
Kaneto et al. 2020 · Diabetes, obesity & metabolism · 512 people · cited by 32
6 results
People
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Riddle et al. 2013 · Diabetes care · 495 people · cited by 239
10 results

All 116 Lixisenatide studies

Lixisenatide clinical trials

ClinicalTrials.gov lists 67 trials of lixisenatide. 5 are active or planned, and 27 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Phase 3completed6,068 people

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Phase 3completed1,170 people

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Phase 3completed894 people

All 47 Lixisenatide trials

Status and safety

Is lixisenatide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Withdrawn

Withdrawn.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US (Adlyxin, 2016). The FDA label for Adlyxin says: “Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus” No central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Lixisenatide side effects and safety

PepBank has 164 safety results from studies of lixisenatide. 163 of them come from studies in people.

Safety results from studies (164)

During Ramadan fasting, symptomatic low blood sugar was numerically lower with lixisenatide (3.3%) than with sulfonylurea (8.9%), each with basal insulin. (Diabetes research and clinical practice, 2019)
In Japanese patients with diabetes, nausea was less frequent with two-step lixisenatide than one-step lixisenatide through week 24. (Journal of diabetes and its complications, 2015)
In patients with diabetes on basal insulin, adverse events were more frequent with lixisenatide than placebo. (Diabetes, obesity & metabolism, 2018)
In patients with diabetes, hypoglycemic events did not increase with LixiLan compared with insulin glargine. (Diabetes care, 2016)
Doubling of a kidney blood marker was numerically more frequent with lixisenatide than placebo, but the difference was not statistically significant. (The lancet. Diabetes & endocrinology, 2018)
In patients with diabetes, hypoglycaemia incidence showed no major differences between iGlarLixi and insulin glargine. (Diabetes, obesity & metabolism, 2017)
In patients with diabetes and recent coronary events, death rates did not differ significantly between lixisenatide and placebo. (The New England journal of medicine, 2015)
In patients with diabetes, symptomatic hypoglycaemia rates were generally comparable between lixisenatide and placebo. (Diabetes/metabolism research and reviews, 2015)
The low blood sugar index did not change with lixisenatide compared with placebo in patients receiving basal insulin. (Diabetes, obesity & metabolism, 2017)
In adults with diabetes on metformin, adverse events, including serious ones, occurred at similar rates with lixisenatide and exenatide. (Diabetes care, 2013)
In Japanese patients with type 2 diabetes, symptomatic low blood sugar was recorded in 14.2% with iGlarLixi and 12.3% with glargine. (Diabetes, obesity & metabolism, 2020)
In Japanese adults with type 2 diabetes, symptomatic low blood sugar occurred more often with iGlarLixi than glargine. (Diabetes, obesity & metabolism, 2020)
In patients with diabetes on basal insulin, symptomatic low glucose was more frequent with lixisenatide than placebo. (Diabetes care, 2013)
In patients with diabetes on pioglitazone, adverse events were numerically lower with lixisenatide than placebo, with similar proportions. (Diabetes, obesity & metabolism, 2013)
In patients with diabetes on basal insulin, nausea was more common with lixisenatide than placebo. (Diabetes care, 2013)
In patients with diabetes on metformin, pulse increased less with lixisenatide than liraglutide. (Diabetes care, 2016)
In Asian patients with diabetes, adverse events were more frequent with lixisenatide than placebo. (Diabetes/metabolism research and reviews, 2014)
In patients with diabetes, nausea was more frequent with lixisenatide than placebo. (Diabetes care, 2012)
Low blood sugar was more frequent with lixisenatide than placebo in nonfrail older patients with type 2 diabetes. (Diabetes care, 2017)
In Japanese patients with type 2 diabetes, symptomatic low blood sugar occurred less often with lixisenatide than insulin glargine/lixisenatide. (Diabetes care, 2020)
In young obese patients with diabetes, adverse events were numerically higher with lixisenatide than sitagliptin, with similar incidence. (Journal of clinical & translational endocrinology, 2014)
In Indian adults fasting during Ramadan, symptomatic low blood sugar was numerically less frequent with lixisenatide than sulphonylurea, both with insulin. (Diabetes research and clinical practice, 2020)
In patients with diabetes on metformin, adverse events were less frequent with lixisenatide than liraglutide. (Diabetes, obesity & metabolism, 2013)
In patients with diabetes on insulin glargine, symptomatic low blood sugar occurred more often with lixisenatide than liraglutide. (Diabetes care, 2015)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
20 μg once daily	Human	human	Not reported	24 weeks	Randomized trial in people · n = 634	Rosenstock 2013
20 μg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 495	Riddle 2013
20 µg once daily	Human	human	Not reported	24 weeks	Randomized trial in people · n = 484	Pinget 2013
20 µg	Human	human	Not reported	24 weeks	Randomized trial in people · n = 446	Riddle 2013
20 µg once daily	Human	human	Not reported	26 weeks	Randomized trial in people · n = 404	Nauck 2016
20 µg once daily	Human	human	Not reported	24 weeks	Randomized trial in people · n = 391	Yu 2014
20 μg once daily before breakfast	Human	human	Not reported	24 weeks	Randomized trial in people · n = 350	Meneilly 2017
Fixed-ratio LixiLan, 2 units insulin glargine to 1 µg lixisenatide once daily; started at 10 units/5 µg and titrated to fasting plasma glucose	Human	human	Not reported	24 weeks	Randomized trial in people · n = 323	Rosenstock 2016
20 μg once daily	Human	human	injection	24 weeks	Randomized trial in people · n = 319	Van 2014
10 µg once daily weeks 1-2, then 20 µg once daily	Human	human	subcutaneous	28 days	Randomized trial in people · n = 148	Kapitza 2013
10 µg initially, increased weekly by 5 µg to 20 µg once daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 136	Yamada 2017
20 μg/day	Human	human	Not reported	24 weeks	Randomized trial in people · n = 127	Onishi 2015
20 μg/day	Human	human	Not reported	12 weeks	Randomized trial in people · n = 38	Otowa-Suematsu 2018
20 µg	Human	human	Not reported	8 weeks	Randomized trial in people · n = 35	Tonneijck 2017
5 μg in iGlarLixi 5 U/5 μg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 20	Inoue 2019
20 µg once daily	Human	human	Not reported	24 weeks	Randomized trial in people	Seino 2012
20 µg once daily	Human	human	Not reported	8 weeks	Randomized trial in people	Meier 2015
20 μg once daily after titration	Human	human	subcutaneous	12 weeks	Randomized trial in people	Fonseca 2012
5 microg once daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
10 microg once daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
20 microg once daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
30 microg once daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
5 microg twice daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
10 microg twice daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
20 microg twice daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
30 microg twice daily	Human	human	subcutaneous	13 weeks	Randomized trial in people	Ratner 2010
20 μg once-daily	Human	human	Not reported	24 weeks	Randomized trial in people	Rosenstock 2014
5 to 30 µg once daily	Human	human	Not reported	5 to 6 weeks	Randomized trial in people	Seino 2014
5 to 30 µg twice daily	Human	human	Not reported	5 to 6 weeks	Randomized trial in people	Seino 2014
20 μg once daily	Human	human	Not reported	24 weeks	Randomized trial in people · n = 108	Dailey 2019
20 μg	Human	human	Not reported	8 weeks	Randomized trial in people · n = 35	Tonneijck 2019
20 μg once daily	Human	human	Not reported	8 weeks	Randomized trial in people · n = 34	Tonneijck 2018
10-20 μg daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 6,063	Muskiet 2018
20 µg once daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 3,188	Raccah 2015
5-20 μg, increased every fifth day by 2.5 μg	Human	human	subcutaneous	28 days	Randomized trial in people · n = 43	Lorenz 2013
2.5, 5, 10 or 20 µg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 20	Becker 2015
≥5 µg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 20	Becker 2015
10 μg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 15	Jones 2019
10 mcg	Human	human	subcutaneous	single dose	Randomized trial in people · n = 15	Jalleh 2020
10 μg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 15	Marathe 2022

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The US label describes adjunctive glucose control in adults with type 2 diabetes mellitus. This record selects the single-ingredient Adlyxin initiation regimen.

Reported routines and cautions

What people use it for

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusS1

Reported regimens

Regimens that community sources report for Lixisenatide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Initiation of single-ingredient Adlyxin in adults with type 2 diabetes mellitus, as an adjunct to diet and exerciseOfficial label dosing of an approved product	subcutaneous injectionInject in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.	10 mcg per dose	once daily within one hour before the first meal of the day	14 days before the labeled increase to 20 mcg once daily	Single official US label source.	S1

Cautions

The label warns about pancreatitis, serious hypersensitivity, and hypoglycemia with insulin or insulin secretagogues.S1
The March 2026 label states that initiation reduces gastrointestinal adverse reactions and is not effective for glycemic control in adults.S3
The current label warns about acute kidney injury due to volume depletion, severe gastrointestinal reactions, immunogenicity, gallbladder disease, and pulmonary aspiration during anesthesia or deep sedation. It does not recommend use in severe gastroparesis or end stage renal disease.S3
The label contraindicates use with known severe hypersensitivity to lixisenatide or any Adlyxin component. Never share a pen. Concomitant insulin or insulin secretagogues may require dose reduction. Delayed gastric emptying can affect oral medicines.S3

Status notes

The EU withdrew the single-ingredient Lyxumia authorisation on 18 December 2025 for commercial reasons. Insulin combination products have separate status.S2

Community sources

S1Adlyxin US prescribing information, September 2023 (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu
S3Adlyxin US prescribing information, March 2026 (opens in a new tab)accessdata.fda.gov

Gaps

This record covers one selected official label regimen. It does not establish a separate community practice regimen. The March 2026 FDA label retains the selected regimen and adds initiation and safety information. The full label contains other administration, interaction, and patient-specific conditions. US marketing availability remains unverified.

Questions and more

Ask a question about lixisenatide

The answer links to every study it uses.

What does the evidence say about lixisenatide?Is lixisenatide tested in people?Compare with Semaglutide Compare with Liraglutide

Sources

Database: PepBank data for lixisenatide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about lixisenatide

Lixisenatide

ApprovedNot banned in sport

Also known as Adlyxin, Lyxumia

What it is

Synthetic analog, 44 amino acids

Approval

Approved in the US (Adlyxin, 2016)

In sport

Not listed as banned by WADA

Studies

116 studies with results. 115 of them gave lixisenatide, with 768 results.
652 in people84 in animals32 in lab cells

Best study in people

Randomized controlled trial with 6,068 people (2015)

Clinical trials

67 registered: 5 active or planned, 27 with posted results

Community use

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dose as reported

Class

Species

Route

Duration

Design

Source

20 μg once daily

Human

human

Not reported

24 weeks

Randomized trial in people · n = 634

Rosenstock 2013

20 μg

Human

human

Not reported

24 weeks

Randomized trial in people · n = 495

Riddle 2013

20 µg once daily

Human

human

Not reported

24 weeks

Randomized trial in people · n = 484

Pinget 2013

20 µg

Human

human

Not reported

24 weeks

Randomized trial in people · n = 446

Riddle 2013

20 µg once daily

Human

human

Not reported

26 weeks

Randomized trial in people · n = 404

Nauck 2016

20 µg once daily

Human

human

Not reported

24 weeks

Randomized trial in people · n = 391

Yu 2014

20 μg once daily before breakfast

Human

human

Not reported

24 weeks

Randomized trial in people · n = 350

Meneilly 2017

Fixed-ratio LixiLan, 2 units insulin glargine to 1 µg lixisenatide once daily; started at 10 units/5 µg and titrated to fasting plasma glucose

Human

human

Not reported

24 weeks

Randomized trial in people · n = 323

Rosenstock 2016

20 μg once daily

Human

human

injection

24 weeks

Randomized trial in people · n = 319

Van 2014

10 µg once daily weeks 1-2, then 20 µg once daily

Human

human

subcutaneous

28 days

Randomized trial in people · n = 148

Kapitza 2013

10 µg initially, increased weekly by 5 µg to 20 µg once daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 136

Yamada 2017

20 μg/day

Human

human

Not reported

24 weeks

Randomized trial in people · n = 127

Onishi 2015

20 μg/day

Human

human

Not reported

12 weeks

Randomized trial in people · n = 38

Otowa-Suematsu 2018

20 µg

Human

human

Not reported

8 weeks

Randomized trial in people · n = 35

Tonneijck 2017

5 μg in iGlarLixi 5 U/5 μg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 20

Inoue 2019

20 µg once daily

Human

human

Not reported

24 weeks

Randomized trial in people

Seino 2012

20 µg once daily

Human

human

Not reported

8 weeks

Randomized trial in people

Meier 2015

20 μg once daily after titration

Human

human

subcutaneous

12 weeks

Randomized trial in people

Fonseca 2012

5 microg once daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

10 microg once daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

20 microg once daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

30 microg once daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

5 microg twice daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

10 microg twice daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

20 microg twice daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

30 microg twice daily

Human

human

subcutaneous

13 weeks

Randomized trial in people

Ratner 2010

20 μg once-daily

Human

human

Not reported

24 weeks

Randomized trial in people

Rosenstock 2014

5 to 30 µg once daily

Human

human

Not reported

5 to 6 weeks

Randomized trial in people

Seino 2014

5 to 30 µg twice daily

Human

human

Not reported

5 to 6 weeks

Randomized trial in people

Seino 2014

20 μg once daily

Human

human

Not reported

24 weeks

Randomized trial in people · n = 108

Dailey 2019

20 μg

Human

human

Not reported

8 weeks

Randomized trial in people · n = 35

Tonneijck 2019

20 μg once daily

Human

human

Not reported

8 weeks

Randomized trial in people · n = 34

Tonneijck 2018

10-20 μg daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 6,063

Muskiet 2018

20 µg once daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 3,188

Raccah 2015

5-20 μg, increased every fifth day by 2.5 μg

Human

human

subcutaneous

28 days

Randomized trial in people · n = 43

Lorenz 2013

2.5, 5, 10 or 20 µg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 20

Becker 2015

≥5 µg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 20

Becker 2015

10 μg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 15

Jones 2019

10 mcg

Human

human

subcutaneous

single dose

Randomized trial in people · n = 15

Jalleh 2020

10 μg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 15

Marathe 2022

Context

Route

Amount

How often

How long

Agreement

Sources

Initiation of single-ingredient Adlyxin in adults with type 2 diabetes mellitus, as an adjunct to diet and exerciseOfficial label dosing of an approved product

subcutaneous injectionInject in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.

10 mcg per dose

once daily within one hour before the first meal of the day

14 days before the labeled increase to 20 mcg once daily

Single official US label source.

Lixisenatide

Lixisenatide at a glance

What is lixisenatide?

The history of lixisenatide

Lixisenatide structure and chemistry

What lixisenatide studies show

Blood sugar

Weight and appetite

Kidneys and bladder

Stomach and gut

Heart and blood vessels

Cholesterol and blood fats

Key lixisenatide studies

Lixisenatide clinical trials

Is lixisenatide approved?

Lixisenatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about lixisenatide

Related peptides

Sources

Lixisenatide

Lixisenatide at a glance

What is lixisenatide?

The history of lixisenatide

Lixisenatide structure and chemistry

What lixisenatide studies show

Blood sugar

Weight and appetite

Kidneys and bladder

Stomach and gut

Heart and blood vessels

Cholesterol and blood fats

Key lixisenatide studies

Lixisenatide clinical trials

Is lixisenatide approved?

Lixisenatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about lixisenatide

Related peptides

Sources